Edinburgh-based Lentitek has secured £250,000 in seed investment.
This investment will be deployed to further advance its technology and commence initial commercial trials.
Founded in 2019 by Dr Adam Inche, the start-up is focused on solving key issues within the manufacturing process of lentiviral vectors, one of the key components of treatments such as CAR-T cell therapy and gene therapies which can provide treatments for previously intractable cancers and other genetic conditions.
